World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 17 October 2023
Main ID:  JPRN-UMIN000022688
Date of registration: 13/06/2016
Prospective Registration: No
Primary sponsor: National Center for Child Health and Development
Public title: A pilot study of reduced intensity conditioning allogeneic stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease
Scientific title: A pilot study of reduced intensity conditioning allogeneic stem cell transplantation with dose-adjusted busulfan for chronic granulomatous disease - A pilot study of RIC-SCT for CGD
Date of first enrolment: 2016/06/10
Target sample size: 9
Recruitment status: Complete: follow-up complete
URL:  https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026149
Study type:  Interventional
Study design:  Single arm Non-randomized  
Phase:  Not selected
Countries of recruitment
Japan
Contacts
Name: Motohiro    Kato
Address:  2-10-1, Okura, Setagaya, Tokyo Japan
Telephone: 03-3416-1811
Email: kato-mt@ncchd.go.jp
Affiliation:  National Center for Child Health and Development Children's Cancer Center
Name: Motohiro    Kato
Address:  2-10-1, Okura, Setagaya, Tokyo 157-8535 Japan
Telephone: 03-3416-1811
Email: kato-mt@ncchd.go.jp
Affiliation:  National Center for Child Health and Development Children's Cancer Center
Key inclusion & exclusion criteria
Inclusion criteria:
Exclusion criteria: 1. Intracranial hemorrhage 2. Severe psychological disorders 3. Pregnant or suspected pregnancy 4. Not eligible for this study at the discretion of the investigator.

Age minimum: Not applicable
Age maximum: 25years-old
Gender: Male and Female
Health Condition(s) or Problem(s) studied
Chronic granulomatous disease
Intervention(s)
Conditioning regimen with targeted-busulfan and fludarabin Total body irradiation (3Gy) at day -1 Stem cell transplantation at day 0
Primary Outcome(s)
Event free survival at day 100
Secondary Outcome(s)
1. Engraftment probability at day 30 2. Mortality at day 100 3. Incidence of infectious disease at week 8 4. Reconstruction of immune status 5. Time from transplantation to onset of acute GVHD 6. Reconstruction of neutrophil function
Secondary ID(s)
Source(s) of Monetary Support
National Center for Child Health and Development
Secondary Sponsor(s)
Ethics review
Status: YES
Approval date: 26/05/2016
Contact:
rinri@ncchd.go.jp
National Center for Child Health and Development
03-3416-0181
rinri@ncchd.go.jp
Results
Results available: Yes
Date Posted:
Date Completed: 28/06/2018
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history